ARTICLE | Clinical News
RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring
July 5, 2017 7:46 PM UTC
RXi Pharmaceuticals Corp. (NASDAQ:RXII) completed enrollment of about 9 patients with advanced wet age-related macular degeneration (AMD) in the Phase I/II Study RXI-109-1501 evaluating once-monthly intravitreal RXI-109 for 4 months to reduce the progression of subretinal fibrosis.
The open-label, dose-escalation, U.S. trial will assess safety and pharmacokinetics. Secondary endpoints will measure changes in lesions through optical coherence tomography (OCT), fluorescein angiography and changes in best corrected visual acuity (BCVA)...
BCIQ Company Profiles
BCIQ Target Profiles